BiotechTube
QLSF Biotherapeutics

QLSF Biotherapeutics

San Diego, United States· Est.
qlsfbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

QLSF Biotherapeutics is a private, clinical-stage biotech founded in 2020 and headquartered in South San Francisco, California. The company has built a robust pipeline of novel bispecific antibodies and cytokine fusion proteins targeting multiple immune-oncology mechanisms, with several programs already in Phase 1/2 clinical trials. Its strategy is driven by tumor biology, categorizing approaches for 'Myeloid Rich,' 'Immunologically Cold,' and 'Inflamed' tumor microenvironments. QLSF benefits from strong financial and clinical development support from a strategic partner, Qilu Pharmaceutical, which is advancing key assets in clinical studies.

Oncology

Technology Platform

Rational design platform for modular antibody-based molecules (bispecifics, cytokine fusions) targeting tumor microenvironments (Myeloid Rich, Immunologically Cold, Inflamed). Includes next-gen T Cell Engager platforms (TECOS, TECAD).

Funding History

1
Total raised:$50M
Series A$50M

Opportunities

The company has multiple clinical-stage assets addressing high-need oncology mechanisms, providing several shots on goal.
Its strategic partnership with Qilu Pharmaceutical provides financial stability and development capabilities, accelerating its path to clinical proof-of-concept.
The novel TECOS/TECAD platforms represent potential best-in-class TCEs for future development.

Risk Factors

High clinical development risk inherent to novel oncology biologics, with potential for efficacy or safety failures.
Significant competition in the bispecific antibody and TCE space from larger, well-resourced companies.
Strategic dependency on a single partner, Qilu Pharmaceutical, for funding and development.

Competitive Landscape

QLSF operates in the highly competitive bispecific antibody and T cell engager space, facing large pharma (e.g., Roche, Amgen) and numerous biotechs. Its differentiation lies in its tumor-biology-driven strategy and novel constructs like PD-L1xCD47 and conditional 4-1BB/IL-15 fusions. Success will require demonstrating superior clinical profiles versus established and emerging competitors.

More companies in Biologics / Biosimilars →More companies in United States →